← All trials
NCT05045144
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2021
- Primary completion
- Dec 23, 2021
- Completion date
- May 29, 2022
- First posted
- Sep 16, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 1541
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.